Humira Managed Care Coverage At 95%; Abbott Raises Sales Forecast
Executive Summary
Abbott's Humira is being reimbursed by 95% of managed care organizations three months after the launch of the tumor necrosis factor inhibitor for rheumatoid arthritis
You may also be interested in...
Humira Takes Nearly 20% Of Enbrel Share; Abbott Eyes Psoriasis Market Next
Abbott sees psoriasis as the next large market opportunity for Humira after rheumatoid arthritis, Immunology General Manager Tim Walbert said during Abbott's R&D Day in New York May 29
Humira Takes Nearly 20% Of Enbrel Share; Abbott Eyes Psoriasis Market Next
Abbott sees psoriasis as the next large market opportunity for Humira after rheumatoid arthritis, Immunology General Manager Tim Walbert said during Abbott's R&D Day in New York May 29
Tidbits From The SG Cowen Health Care Conference
King/Elan deal in jeopardy?: King is "evaluating the effect" that FTC's investigation into Elan's Skelaxin will have on its proposed acquisition of Elan's primary care business. King is "evaluating what our rights are under our contract," company says at SG Cowen March 19. FTC opened an investigation into Elan's "Orange Book" patent listings for the muscle relaxant (1"The Pink Sheet" March 17, In Brief). King reiterated that it will not purchase the sleep agent Sonata as a stand-alone product. "The transaction is not structured that way." The $850 mil. deal, which has a deadline of July 31, would add 400 sales reps to King's 800-person force ("The Pink Sheet" Feb. 3, p. 29)...